Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

BioDelivery Sciences Intl, Inc. Wrrt

BDSIWNASDAQ
Healthcare
Drug Manufacturers - General
$0.04
$0.00(0.00%)
U.S. Market is Open • 12:43

BioDelivery Sciences Intl, Inc. Wrrt Fundamental Analysis

BioDelivery Sciences Intl, Inc. Wrrt (BDSIW) shows strong financial fundamentals with a PE ratio of 6.80, profit margin of 50.90%, and ROE of 57.33%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

ROE57.33%
Operating Margin22.27%
PEG Ratio0.07
Current Ratio2.45

Areas of Concern

No major concerns flagged.
We analyze BDSIW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 78.1/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
78.1/100

We analyze BDSIW's fundamental strength across five key dimensions:

Efficiency Score

Excellent

BDSIW demonstrates superior asset utilization.

ROA > 10%
26.14%

Valuation Score

Excellent

BDSIW trades at attractive valuation levels.

PE < 25
6.80
PEG Ratio < 2
0.07

Growth Score

Weak

BDSIW faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

BDSIW maintains a strong and stable balance sheet.

Debt/Equity < 1
0.31
Current Ratio > 1
2.45

Profitability Score

Moderate

BDSIW maintains healthy but balanced margins.

ROE > 15%
57.33%
Net Margin ≥ 15%
50.90%
Positive Free Cash Flow
N/A

Key Financial Metrics

Is BDSIW Expensive or Cheap?

P/E Ratio

BDSIW trades at 6.80 times earnings. This suggests potential undervaluation.

6.80

PEG Ratio

When adjusting for growth, BDSIW's PEG of 0.07 indicates potential undervaluation.

0.07

Price to Book

The market values BioDelivery Sciences Intl, Inc. Wrrt at 3.07 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.07

EV/EBITDA

Enterprise value stands at 14.20 times EBITDA. This signals the market has high growth expectations.

14.20

How Well Does BDSIW Make Money?

Net Profit Margin

For every $100 in sales, BioDelivery Sciences Intl, Inc. Wrrt keeps $50.90 as profit after all expenses.

50.90%

Operating Margin

Core operations generate 22.27 in profit for every $100 in revenue, before interest and taxes.

22.27%

ROE

Management delivers $57.33 in profit for every $100 of shareholder equity.

57.33%

ROA

BioDelivery Sciences Intl, Inc. Wrrt generates $26.14 in profit for every $100 in assets, demonstrating efficient asset deployment.

26.14%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $0.39 in free cash annually.

$0.39

FCF Yield

BDSIW converts 7.04% of its market value into free cash.

7.04%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

6.80

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.07

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.07

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.46

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.31

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.45

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.57

vs 25 benchmark

ROA

Return on assets percentage

0.26

vs 25 benchmark

ROCE

Return on capital employed

0.15

vs 25 benchmark

How BDSIW Stacks Against Its Sector Peers

MetricBDSIW ValueSector AveragePerformance
P/E Ratio6.8029.43 Better (Cheaper)
ROE57.33%800.00% Weak
Net Margin50.90%-20145.00% (disorted) Strong
Debt/Equity0.310.30 Neutral
Current Ratio2.454.64 Strong Liquidity
ROA26.14%-17936.00% (disorted) Strong

BDSIW outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews BioDelivery Sciences Intl, Inc. Wrrt's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ